技術(shù)文章您現(xiàn)在的位置：首頁(yè) > 技術(shù)文章 > RecombiMAb anti-mouse PD-1 (CD279)（29F.1A12™-CP004單克隆抗體）介紹

RecombiMAb anti-mouse PD-1 (CD279)（29F.1A12™-CP004單克隆抗體）介紹

更新時(shí)間：2024-09-13 點(diǎn)擊次數(shù)：711次

29F.1A12™-CP004單克隆抗體是原始29F.1A12™克隆號(hào)的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始29F.1A12™克隆號(hào)相同，但是恒定區(qū)序列已經(jīng)從大鼠IgG2a變?yōu)樾∈驣gG1。29F.1A12™-CP004抗體像原始大鼠IgG2a抗體一樣無(wú)Fc突變。

29F.1A12™-CP004單克隆抗體與小鼠PD-1（程序性死亡-1蛋白，也稱為CD279）反應(yīng)。PD-1是一種50-55 kDa的細(xì)胞表面受體，由Pdcd1基因編碼，屬于免疫球蛋白超家族的CD28家族。PD-1在CD4和CD8胸腺細(xì)胞以及活化的T和B淋巴細(xì)胞和骨髓細(xì)胞上瞬時(shí)表達(dá)。成功清除抗原后，PD-1表達(dá)下降。此外，Pdcd1 mRNA在前B細(xì)胞階段發(fā)育中的B淋巴細(xì)胞中表達(dá)。PD-1的結(jié)構(gòu)包括一個(gè)ITIM(免疫受體酪氨酸抑制基序),表明PD-1負(fù)調(diào)節(jié)TCR信號(hào)。PD-1通過(guò)結(jié)合它的兩個(gè)配體PD-L1和PD-L2發(fā)出信號(hào)，這兩個(gè)配體都是B7家族的成員。配體結(jié)合后，PD-1信號(hào)抑制T細(xì)胞活化，導(dǎo)致增殖、細(xì)胞因子產(chǎn)生和T細(xì)胞死亡減少。此外，已知PD-1在小鼠的外周耐受性和預(yù)防自身免疫性疾病中起關(guān)鍵作用，因?yàn)镻D-1敲除動(dòng)物表現(xiàn)出擴(kuò)張性心肌病、脾腫大和外周耐受性喪失。誘導(dǎo)的PD-L1表達(dá)常見于許多腫瘤，包括鱗狀細(xì)胞癌、結(jié)腸腺癌和乳腺腺癌。PD-L1過(guò)度表達(dá)導(dǎo)致腫瘤細(xì)胞對(duì)CD8 T細(xì)胞介導(dǎo)的裂解的抗性增加。在黑色素瘤的小鼠模型中，通過(guò)用阻斷PD-L1和它的受體PD-1之間的相互作用，腫瘤生長(zhǎng)可以暫時(shí)被抑制。目前PD-1是癌癥免疫療法的熱門靶點(diǎn)之一。

產(chǎn)品詳情：

產(chǎn)品名稱	RecombiMAb anti-mouse PD-1 (CD279)
產(chǎn)品貨號(hào)	CP004
產(chǎn)品規(guī)格	1mg
反應(yīng)種屬	Mouse
克隆號(hào)	29F.1A12™-CP004
同種型	Mouse IgG1(switched from rat IgG2a)
免疫原	Recombinant PD-1-Ig fusion protein
實(shí)驗(yàn)應(yīng)用	in vivo blocking of PD-1/PD-L signaling* in vitro PD-1 neutralization* Immunohistochemistry (frozen)* Immunofluorescence* Western blot* Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody
產(chǎn)品形式	PBS, pH 7.0,Contains no stabilizers or preservatives
純度	>95%, Determined by SDS-PAGE
聚合	<5%, Determined by SEC
無(wú)菌處理	0.2 µm filtration
純化方式	Protein G
分子量	150 kDa
小鼠病原檢測(cè)	Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative
保存條件	抗體原液保存在4°C，不能冷凍保存。
推薦同型對(duì)照	InVivoPlus mouse IgG1 isotype control, unknown specificity（貨號(hào)BP0083）
推薦抗體稀釋液	InVivoPure pH 7.0 Dilution Buffer（貨號(hào)IP0070）

該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：

應(yīng)用

文章

體內(nèi)PD-1/PD-L信號(hào)阻斷

(in vivo blocking of PD-1/

PD-L signaling)

1. Wang, W., et al. (2018). 'RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune

Tolerance in Pancreatic Cancer' Cancer Cell 34(5): 757-774 e757.

2. Gordon, S. R., et al. (2017). 'PD-1 expression by tumour-associated macrophages

inhibits phagocytosis and tumour immunity' Nature 545(7655): 495-499.

3. Koyama, S., et al. (2016). 'STK11/LKB1 Deficiency Promotes Neutrophil Recruitment

and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor

Microenvironment' Cancer Res 76(5): 999-1008.

體內(nèi)PD-1/PD-L信號(hào)阻斷，

流式細(xì)胞術(shù)

(in vivo blocking of PD-1/

PD-L signaling, Flow Cytometry)

1.Koyama, S., et al. (2016). 'Adaptive resistance to therapeutic PD-1 blockade is

associated with upregulation of alternative immune checkpoints' Nat Commun 7: 10501.

體外PD-1中和

（in vitro PD-1 neutralization）

1.Park, S. J., et al. (2014). 'Negative role of inducible PD-1 on survival of activated

dendritic cells' J Leukoc Biol 95(4): 621-629.

體內(nèi)PD-1/PD-L信號(hào)阻斷，

體外PD-1中和（in vivo blocking

of PD-1/PD-L signaling, in vitro

PD-1 neutralization）

1.Duraiswamy, J., et al. (2013). 'Dual blockade of PD-1 and CTLA-4 combined with

tumor vaccine effectively restores T-cell rejection function in tumors' Cancer Res 73

(12): 3591-3603.

流式細(xì)胞術(shù)

（Flow Cytometry）

1.Good-Jacobson, K. L., et al. (2012). 'CD80 expression on B cells regulates murine

T follicular helper development, germinal center B cell survival, and plasma cell

generation' J Immunol 188(9): 4217-4225.

<a class=

更多產(chǎn)品詳情請(qǐng)聯(lián)系BioXCell 中國(guó)授權(quán)代理——欣博盛生物

上一篇：RecombiMAb anti-mouse CTLA-4 (CD152)（9D9-CP006單克隆抗體）介紹

下一篇：Epicypher產(chǎn)品介紹：SMARCA2 Chromatin Remodeling Enzyme (Human BRM)

返回列表>>